MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Book Value 2011-2026 | QTNT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -35.6 M | -5.53 M | 1.71 M | -14.6 M | -24.1 M | 46.7 M | -1.62 M | -31.5 M | -23.1 M | -18.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.7 M | -35.6 M | -10.6 M |
Quarterly Book Value Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -209 M | -182 M | -151 M | -144 M | -126 M | -85.3 M | -61.2 M | -51.7 M | 2.24 M | 7.67 M | 33.7 M | -30.2 M | 18.1 M | -46.9 M | -21.2 M | 1.71 M | 24.7 M | -14.7 M | -36.2 M | -14.6 M | 3.82 M | -16.4 M | 4.47 M | -24.1 M | -5.08 M | 27.4 M | 27.9 M | 46.7 M | 26.1 M | 9.66 M | -8.36 M | -1.62 M | -7.94 M | 9.9 M | 23.4 M | -773 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 46.7 M | -209 M | -27 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
5.39 B | $ 114.29 | -1.06 % | $ 34.7 B | USA |
 |
CareDx, Inc
CDNA
|
303 M | $ 20.76 | -0.24 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 1.52 | -1.93 % | $ 2.02 M | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 24.29 | -0.82 % | $ 675 M | USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 14.56 | -4.15 % | $ 440 M | USA |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 117.06 | -0.98 % | $ 9.66 B |  Irlanda |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 130.6 | 3.04 % | $ 20.8 B | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 84.44 | -0.21 % | $ 5.7 B | USA |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 165.26 | -0.95 % | $ 8.19 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 415.68 | -0.71 % | $ 12 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
837 M | $ 9.17 | -0.97 % | $ 1.17 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 16.56 | 0.58 % | $ 371 M | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 86.39 | -0.8 % | $ 10.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 26.38 | -0.04 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Personalis
PSNL
|
203 M | $ 5.46 | -1.09 % | $ 324 M | USA |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.74 | -0.21 % | $ 439 M | USA |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
Senseonics Holdings
SENS
|
61 M | $ 5.27 | -20.27 % | $ 220 M | USA |
 |
Soleno Therapeutics
SLNO
|
450 M | $ 52.85 | 0.06 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
4.1 M | $ 2.18 | - | $ 5.01 M | USA |
 |
Thermo Fisher Scientific
TMO
|
110 B | $ 472.28 | -1.43 % | $ 178 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 256.18 | -0.27 % | $ 21.3 B | USA |
 |
Twist Bioscience Corporation
TWST
|
473 M | $ 58.12 | -0.56 % | $ 3.48 B | USA |
 |
Celcuity
CELC
|
101 M | $ 119.1 | -1.85 % | $ 5.57 B | USA |
 |
Natera
NTRA
|
706 M | $ 201.11 | -2.45 % | $ 19.8 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 9.3 | -1.12 % | $ 2.02 B | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
2.56 B | $ 306.27 | -0.98 % | $ 18.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 193.76 | -0.38 % | $ 21.5 B | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |